Vitro Biopharma, Inc

About Us

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, MSC-Gro™ optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. to jointly manufacture and distribute LUMENESC™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vitro Biopharma Signs Agreement with Stemgenesis for Distribution of its Stem Cell Products in China

Wed, Sep 12, 2012 14:30 CET

Golden, Colorado—September 12, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced an agreement with Stemgenesis, Inc. for the exclusive distribution of its products into the following Chinese Provinces: Shanghai, Beijing, Tianjin, Jiangsu, Shandong, Zhejiang, Anhui, Fujian, Hebei, Liaoning and Heilongjiang. The agreement provides for distribution of the entire Vitro Biopharma product line under specific terms and conditions. The agreement covers Vitro Biopharma’s adult mesenchymal stem cell (MSC) lines & derivatives, the MSC-Gro™

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Vitro Biopharma Signs Agreement with Stemgenesis for Distribution of its Stem Cell Products in China

Media